NAII · Natural Alternatives International Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | $120.57M | $106.93M | $135.86M | $140.46M | $148.08M | $100.00M |
| Gross Profit | $9.29M | $6.87M | $18.16M | $30.51M | $30.44M | $18.87M |
| R&D | $1.80M | $1.90M | $2.10M | $2.50M | $1.90M | $1.80M |
| SG&A | - | - | - | - | - | $17.10M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $4.56M | $4.65M | $4.25M | $4.17M | $4.34M | $3.96M |
| Operating Income | ($8.66M) | ($8.53M) | $4.71M | $13.68M | $13.67M | ($1.51M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $2.83M | ($2.25M) | $1.03M | $2.95M | $1.36M | ($93.0K) |
| Net Income | ($13.57M) | ($7.22M) | $2.52M | $10.71M | $10.77M | ($1.65M) |
| EPS - Basic | ($2.28) | ($1.23) | $0.43 | $1.75 | $1.71 | ($0.25) |
| EPS - Diluted | ($2.28) | ($1.23) | $0.43 | $1.74 | $1.69 | ($0.25) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.32M | $11.98M | $13.60M | $21.83M | $32.13M | $30.48M |
| Accounts Receivable | $14.64M | $16.89M | $7.02M | $17.42M | $17.95M | $17.00M |
| Inventory | $24.87M | $24.25M | $29.69M | $32.48M | $27.01M | $27.97M |
| Accounts Payable | $15.35M | $12.74M | $7.78M | $16.18M | $11.89M | $12.51M |
| Current Assets | $59.28M | $61.61M | $57.01M | $76.75M | $80.35M | $79.02M |
| Total Assets | $151.94M | $162.34M | $134.15M | $146.00M | $120.28M | $120.20M |
| Current Liabilities | $28.80M | $23.46M | $15.88M | $23.26M | $22.07M | $27.81M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $83.51M | $79.75M | $45.38M | $57.48M | $40.20M | $48.83M |
| Stockholders' Equity | $68.43M | $82.59M | $88.77M | $88.52M | $80.08M | $71.38M |
| Retained Earnings | $59.39M | $72.97M | $80.18M | $77.66M | $66.95M | $56.18M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $5.93M | ($1.50M) | $7.02M | $11.87M | $20.81M | $3.69M |
| Investing Cash Flow | ($3.61M) | ($3.02M) | ($13.47M) | ($26.46M) | ($5.04M) | ($4.51M) |
| Financing Cash Flow | ($1.97M) | $2.89M | ($1.78M) | $4.29M | ($14.11M) | $6.25M |
| CapEx | $3.61M | $3.02M | $13.52M | $26.49M | $5.11M | $4.54M |
| Free Cash Flow | $2.32M | ($4.51M) | ($6.50M) | ($14.62M) | $15.70M | ($850.0K) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | -0.17 | 0.63 | -2.58 | -1.37 | 1.46 | 0.52 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | 29.1% | 21.6% | 11.2% | - |
| Return on assets | -8.9% | -4.4% | 1.9% | 7.3% | 9.0% | -1.4% |
| Return on equity | -19.8% | -8.7% | 2.8% | 12.1% | 13.4% | -2.3% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.06 | 2.63 | 3.59 | 3.30 | 3.64 | 2.84 |
| Quick ratio | 1.19 | 1.59 | 1.72 | 1.90 | 2.42 | 1.84 |
| Cash ratio | 0.43 | 0.51 | 0.86 | 0.94 | 1.46 | 1.10 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 2.22 | 1.97 | 1.51 | 1.65 | 1.50 | 1.68 |
| Liabilities / Assets | 0.55 | 0.49 | 0.34 | 0.39 | 0.33 | 0.41 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | 4.85 | 4.41 | 4.58 | 4.33 | 5.48 | 3.58 |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | 75d | 83d | 80d | 84d | 67d | 102d |
| Days payable outstanding | 46d | 43d | 21d | 42d | 29d | 46d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | 16.7x | 6.0x | 10.0x | - |
| P / B | 0.3x | 0.4x | 0.5x | 0.7x | 1.3x | 0.6x |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | 3.2x | 2.4x | 4.2x | 6.3x |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | 35.3% | -62.2% | -40.5% | 0.2% | 61.3% | -20.0% |
| Operating income growth (YoY) | -1.5% | - | -65.5% | 0.1% | - | - |
| Net income growth (YoY) | -88.1% | - | -76.5% | -0.5% | - | - |
| EPS growth (YoY) | -85.4% | - | -75.3% | 3.0% | - | - |
| EPS CAGR (3y) | - | - | - | 23.7% | 32.3% | - |
| EPS CAGR (5y) | - | - | -10.0% | 9.8% | 3.3% | - |
| FCF growth (YoY) | - | 30.6% | 55.5% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -17.2% | -7.0% | 0.3% | 10.5% | 12.2% | -6.2% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Medicinal Chemicals & Botanical Products
Comparing NATURAL ALTERNATIVES INTERNATIONAL INC against the 5 most active filers in the same SIC group.